Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$571K Buy
1,578
+31
+2% +$10.6K 0.14% 82
2026
Q1
$544K Buy
1,547
+8
+0.5% +$2.85K 0.16% 79
2025
Q4
$504K Buy
1,539
+52
+3% +$16.5K 0.15% 82
2025
Q3
$420K Buy
1,487
+70
+5% +$20.3K 0.13% 89
2025
Q2
$396K Sell
1,417
-123
-8% -$34.8K 0.14% 85
2025
Q1
$480K Buy
1,540
+197
+15% +$58.2K 0.19% 67
2024
Q4
$350K Sell
1,343
-31
-2% -$9.2K 0.14% 87
2024
Q3
$443K Sell
1,374
-202
-13% -$66.1K 0.18% 72
2024
Q2
$492K Sell
1,576
-76
-5% -$22.3K 0.22% 64
2024
Q1
$470K Sell
1,652
-190
-10% -$55.6K 0.22% 70
2023
Q4
$531K Sell
1,842
-4,728
-72% -$1.29M 0.27% 57
2023
Q3
$1.77M Buy
6,570
+18
+0.3% +$4.49K 1.02% 19
2023
Q2
$1.45M Buy
6,552
+376
+6% +$87.2K 0.83% 23
2023
Q1
$1.49M Hold
6,176
1.08% 19
2022
Q4
$1.62M Buy
6,176
+65
+1% +$17.4K 1.31% 17
2022
Q3
$1.38M Buy
6,111
+45
+0.7% +$10.9K 1.24% 17
2022
Q2
$1.48M Hold
6,066
1.34% 14
2022
Q1
$1.47M Hold
6,066
1.22% 13
2021
Q4
$1.36M Buy
+6,066
New +$1.28M 1.15% 15

Other funds holding AMGN

Sandy Cove Advisors's AMGN Position: Q2 2026 in Review

Sandy Cove Advisors increased its Amgen (AMGN) stake by 2% in Q2 2026, buying an estimated $10.6K and bringing the position to 1,578 shares worth $571K. The position accounts for 0.14% of the portfolio, ranked #82.

Sandy Cove Advisors first reported a position in AMGN in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.77M in Q3 2023. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Sandy Cove Advisors held 1,578 shares of Amgen worth $571K as of Q2 2026.
  • Sandy Cove Advisors bought 31 Amgen shares in Q2 2026, an estimated $10.6K.
  • Amgen made up 0.14% of Sandy Cove Advisors's portfolio in Q2 2026, its #82 holding.
  • Sandy Cove Advisors first reported a position in Amgen in Q4 2021 and has held it in 19 quarters since.
  • Sandy Cove Advisors's Amgen position peaked at $1.77M in Q3 2023.
  • 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Sandy Cove Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.